Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme -- Ignore unavailable to you. Want to Upgrade?

To: STEWART TAYLOR who wrote (3571)	6/9/1998 1:01:00 PM
From: Alan Coccio	Read Replies (1) \| Respond to of 8798

NEW YORK, June 9 /PRNewswire/ -- The following was issued today by Asensio & Company, Inc.: Asensio & Company, Inc. issued an institutional research report and initiated coverage of Chromatics Color Sciences International, Inc.'s (OTC Bulletin Board: CCSI) common stock with a Strong Sell and Short Sell recommendation. Investors are buying shares of Chromatics Color Sciences International, Inc. believing that the company has developed a proprietary medical instrument, the Colormate III, which offers certain unique advantages in a market it estimates to be between $330 and $510 million. These product and market size claims are completely false and untrue. The Colormate III is a simple, common non-invasive bilirubinometer. Non-invasive bilirubinometers are inexpensive colorimeters adapted to generate estimates of bilirubin blood levels. They have been in use since the 1950's. In fact, the Colormate III itself is over 10 years old, was FDA approved for marketing almost a year ago and has yet to register a single sale. Frost & Sullivan estimates the entire world market for bilirubinometers to be less than $2.5 million per year. Chromatics' widely published claim that this smallest of segments of the clinical laboratory instrument market is over 100 to 200 times its actual size is absurd. ! Chromatics lacks any reasonable or factual support for any of its product and market claims. Any information to the contrary is necessarily false and misleading. We believe that Chromatics has purposely disseminated such false and misleading information in order to defraud investors. We further believe Chromatics' stock rise is based on the belief that the Colormate III has the potential to generate significant earnings. There is no truth to this belief. As a result, we believe the shares will soon trade below $1.00 per share. <snip>